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Abbreviations 
AbTg: anti-thyroglobulin antibodies  
ADMA: asymmetric dimethyl arginine 
AKT : phosphatidylinositol 3-kinase (PI3K)/ serine/threonine-protein kinase  
BMI: body mass index 
COX-2: cyclooxygenase 2  
CFR: Coronary flow reserve  
DBP: diastolic blood pressure 
DTC: differentiated thyroid cancer  
eNOS: endothelial NO synthase  
FMD: Flow-Mediated Vasodilation  
FT3: free Triiodotironine  
FT4: free Thyroxine 
L-NMMA: NG_monomethy-L arginine 
NO : nitric oxide  
PAF: platelet activating factor 
PLN: phospholamban  
rhTSH: recombinant human TSH   
SBP: systolic blood pressure 
SERCA2: sarcoplasmic/endoplasmic reticulum calcium ATPase 2  
SubHypo: subclinical hypothyroidism  
SubHyper: subclinical hyperthyroidism  
T3: Triiodotironine  
T4: Thyroxine 
Tg: thyreoglobulin  
TRAIL: TNF-related apoptosis-inducing ligand 
TSH: Thyrotropin  
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1. Introduction   
 
The relationship between thyroid hormones and cardiovascular system has been 
extensively demonstrated in experimental and clinical studies (1-4). This association 
has been confirmed by significant changes in cardiac structure and function in patients 
with overt or subclinical thyroid dysfunctions (1-11).  The endothelium and vascular 
smooth-muscle cells are biological target of thyroid hormones action and their role 
have been investigated in hypothyroidism and hyperthyroidism reporting different 
results (1-3, 5, 6). 
  
1.1 Thyroid Hormones actions on the heart 
 
Thyroid hormone has many effects on the heart and vascular system via genomic and 
non-genomic effects, affecting chronotropic, inotropic and lusitropic functions (1-3). 
Fig 1 
Triiodotironine (T3), the biological active thyroid hormone, enters into the 
cardiomyocytes through cell membrane transporters and is also produced by the 
intracellular conversion of Thyroxine (T4) by type II deiodinase. T3 binds thyroid 
hormone nuclear receptor with the activation or repression of genes transcription for 
structural and functional cardiac proteins. T3 activates gene expression encoding 
Na/K-transporting ATPases, myosin heavy chain-α (myosin 6, important component 
of the cardiomyocyte contractile apparatus) and sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 (SERCA2). Contrarily, T3 down-regulates the transcription of 
myosin heavy chain-β (myosin 7) and phospholamban (PLN). SERCA2 and its 
5 
 
inhibitor PLN regulate the intracellular calcium concentration, an important 
determinant of both cardiac relaxation and contraction, by acting on calcium reuptake 
and release from the sarcoplasmic reticulum. Thyroid hormones increase SERCA2 
levels and decrease PLN levels promoting cardiomyocytes calcium reuptake during 
diastole, which is the major determinant of the myocardial velocity relaxation after 
contraction (1-3). Thyroid hormones trigger the gene transcriptional activation 
encoding the β1-adrenergic receptor with a direct inotropic effect on the heart (3).  
In addition to these genomic effects, thyroid hormones produce changes in cardiac 
inotropism and chronotropism that are not mediated by the interaction between thyroid 
hormones and their nuclear receptors. These effects, known as non-genomic effects, 
determine ion membrane channel activation (sodium, potassium and calcium), 
activation of phosphatidylinositol 3-kinase (PI3K)/ serine/threonine-protein kinase 
(AKT) resulting in an inhibitory effect of PLN on sarcoplasmic reticulum calcium-
activated ATPase.  
The endothelium and the smooth muscle cells are a biological target of action for 
thyroid hormones with a vasodilator effect. Thyroid hormone acutely decreases 
peripheral vascular resistance by increasing calcium reuptake within the arterioles with 
subsequent smooth muscle relaxation. T3 improves systemic vascular resistance by 
both endothelium-dependent and independent mechanisms (2, 3). Thyroid hormone 
stimulates the production of endothelial nitric oxide with a subsequent reduction in the 
systemic vascular resistance (1-3). Moreover, T3 determinates also vasodilation and 
changes in the renin–angiotensin–aldosterone system by reducing kidneys perfusion. 
Higher renin and aldosterone levels increase plasma volume and  cardiac preload (3). 
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1.2 The endothelium  
 
The endothelium, once considered only a passive interface between blood and vessel 
walls, is now known to be a homeostatic organ with endocrine and paracrine functions. 
It is essential for the regulation of the vascular tone and structure (12). Endothelial 
cells, in fact, are able to synthesize and secrete anti-atherosclerotic substances: nitric 
oxide (NO), endothelium derived hyperpolarizing factor, platelet activating factor 
(PAF), endothelin1prostaciclin, tromboxan A2 and prostaglandine A2. The most 
important of these, NO, is a gas produced through a 5-electron oxidation of the 
guanidine-nitrogen terminal of L-arginine via endothelial NO synthase (eNOS), 
expressed in endothelial cells, in response to shear stress elicited by circulating blood 
(13, 14). NO diffuses to surrounding tissue and cells exerting a cardiovascular 
protective role by relaxing media-smooth muscle cells, preventing leukocyte adhesion 
and migration into the arterial wall, muscle cell proliferation, platelet adhesion and 
aggregation, and adhesion molecule expression (15, 16). An intact endothelial layer is 
crucial in preventing circulating blood cell exposure to prothrombotic subendothelial 
matrix, in avoiding platelet and leukocyte interaction with the vascular wall and in 
inhibiting vascular smooth muscle cell proliferation and migration (17, 18). Moreover, 
a healthy endothelium inhibits arterial thrombus formation. Indeed, NO limits platelet 
activation, adhesion and aggregation, and inhibits the expression of prothrombotic 
protein plasminogen activator inhibitor-1 modulating the balance of profibrinolytic 
and prothrombotic activity (19). Furthermore, platelets have been shown to express 
eNOS and to produce NO that limits platelet recruitment and aggregation. Endothelial 
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prostacyclin production, largely dependent on cyclooxygenase 2 (COX-2), acts 
synergistically with NO to prevent platelet activation (20) Fig.2. 
The NO bioavailability represents the main key marker regarding vascular health (12, 
14). Under pathologic conditions, in fact, the endothelium reduces the availability of 
vasodilating factors, in particular NO, and augments the production of vasoconstricting 
factors, leading to impaired endothelium-dependent vasodilation (12). 
Endothelial dysfunction is a pathological condition characterized by an imbalance 
between substances with vasodilating and antithrombogenic properties and substances 
with vasoconstricting, prothrombotic and proliferative characteristics (16, 21). 
Endothelial dysfunction is involved in the early steps of atherosclerosis development 
(increased lipid permeability and the promotion of oxidative and inflammatory 
environments for atheromatous plaque creation, progression and evolution in necrotic 
plaques particularly vulnerable to rupture) and is associated with an increased risk of 
cardiovascular events (12, 22).  
Presently, no techniques have been developed to allow a direct visualization of the 
coronary microcirculation in vivo in humans. To asses coronary endothelial function 
several invasive and non-invasive techniques are performed to measure parameters 
that are strongly dependent on the functional integrity of the coronary microcirculation 
(23, 24). Table 1  
Despite its key importance in vascular pathophysiology, NO can be hardly assayed 
directly due to its biochemical properties; NO, in fact, is a volatile gas with a short 
half-life (6-7 sec). For this reason, several invasive and non-invasive indirect methods 
for assessing stimulated NO release both in coronary and peripheral vascular districts 
have been developed (14, 23). Endothelial function is usually tested analyzing the 
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degree of change in vessel diameter both in the microcirculation (coronary, peripheral 
muscle, subcutaneous and skin circulation) and in the macrocirculation (epicardial or 
brachial arteries) (23, 24).  
Changes in coronary blood flow can be used as a surrogate parameter for 
microvascular function (21, 25). Coronary flow reserve (CFR) represents the capacity 
of the coronary circulation to dilate following an increase in myocardial demands. It 
could be measured as the ratio between maximal coronary hyperemia with provocative 
stimuli (physical or pharmacological) and coronary flow at rest (26, 27). In normal 
conditions and in the absence of the stenosis coronary blood flow increases 
approximately about 4-6 times as a consequence to the myocardial oxygen 
consumption. This effect, mediated by the arteriolar vasodilatation, causes a reduction 
of vascular resistances and an increase of the coronary blood flow (26).  The 
assessment of CFR by trans-thoracic Doppler method has been established as a 
reliable, inexpensive, non-invasive and easily executable method in clinical practice 
for the evaluation of coronary blood flow at rest and after pharmacological 
(dipyridamole or adenosine) or physical stimulation (Cold pressure test (CPT) (23, 
28). Other methods to evaluate the CFR such as the thermal dilution in the coronary 
sinus, the cardiac nuclear magnetic resonance, positron emission tomography and 
intracoronary Doppler flow wire are rarely used in clinical practice because of high 
costs, high time-consuming, lack of availability and invasiveness (23, 28). 
Quantitative coronary angiography or intravascular ultrasound are methods to evaluate 
epicardial coronary arteries endothelium (23, 26). After pharmacological 
(acetylcholine and salbutamol intracoronary infusion) or physical stimulation (CPT or 
exercise) vessels with an integral endothelium are able to vasodilate with a consequent 
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increase in coronary blood flow. On the contrary in presence of dysfunctional or 
disrupted endothelium there is a decrease in coronary blood flow; acetylcholine 
determinates a vasoconstriction effect on the vascular smooth cells in absence of NO 
release. Although these methods are invasive, expensive, their advantage is to measure 
endothelial function directly in the coronary vascular bed (16). 
Flow-Mediated Vasodilation (FMD) of Brachial Artery is a non-invasive method, 
based on the measurement of percentage change in brachial artery diameters from 
baseline and after an increase in shear stress induced by reactive hyperemia. This 
technique measures the ability of the arteries to respond with endothelial NO release 
following a brief period of reactive hyperemia induced by brachial artery occlusion 
using a blood pressure cuff. The peripheral endothelial function assessed by FMD 
correlates with coronary artery endothelial function (16, 29). 
Plethysmography of the forearm circulation is a semi-invasive technique to measure 
changes in forearm blood flow before and after vasoactive substance infusion 
(vasodilator substances as acetylcholine and nitroglycerin or vasoconstrictor 
substances as noradrenalin and L-NMMA). The variations in forearm blood circulation 
are evaluated by use of a cannulated brachial artery that evaluates venous 
plethysmography (16).  
Measuring endothelial function with peripheral arterial tonometry has been developed 
to quantify observer independent pulsatile arterial volume changes by finger 
plethysmography (EndoPAT) (16). The pulse amplitude increase after reactive 
hyperemia reflects changes in digital microvessel flow and dilatation, only partly 
dependent on NO. The endothelial function alterations in peripheral finger measured 
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by EndoPAT were correlated with coronary microvascular function in patients with 
early atherosclerosis and could predict cardiovascular events (30).  
The correlation between endothelial dysfunction and cardiovascular risk factors has 
been evaluated in several studies. Endothelial dysfunction has been associated with 
hypertension, diabetes mellitus, dyslipidemia, age, hyperhomocysteinemia, smoking, 
and obesity (31-35). A progressive impairment in NO availability has been showed in 
the presence of multiple risk factors, with a probable  additive effect on the 
endothelium (36).  
Endothelial dysfunction has been also analyzed in those patients with thyroid 
dysfunctions.  
 
1.3 Endothelial dysfunction in overt and subclinical Hypothyroidism  
 
Hypothyroidism is a clinical condition characterized by elevated serum Thyrotropin 
(TSH) and low thyroid hormones, while Subclinical Hypothyroidism (SubHypo) 
represents a condition characterized by elevated serum TSH and thyroid hormone 
levels within their respective reference ranges. Dependent on the degree of serum TSH 
increase, SubHypo is divided in two forms: mild (serum TSH increase 4.5–9.9 mU/L) 
or severe (TSH ≥10 mU/L) thyroid hormone deficiency (5, 6).  
Overt and subclinical hypothyroidism are associated with endothelial dysfunction (1-
7). 
Hypothyroidism impairs endothelial function by the reduction of NO availability, 
relaxation of vascular smooth muscle cells with increase in systemic vascular 
resistance and arterial stiffness (1-3, 11, 37-44).  
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Hypothyroidism is associated with microvascular endothelial dysfunction in women. 
The evaluation of endothelial-dependent microvascular and epicardial function in 
coronary artery in response to intracoronary infusions of acetylcholine, showed that 
hypothyroid women presented a microvascular endothelial dysfunction compared to 
euthyroid women. This alteration did not change after adjusting for confounders and 
risk factors and may explain the increased risk of coronary heart disease in these 
patients (37). 
Flow mediated endothelium-dependent vasodilatation, assessed by high-resolution 
ultrasound imaging of the brachial artery, was significantly impaired in hypothyroid 
subjects with SubHypo (TSH levels between 4.01 and 10 mIU/liter, and greater than 
10 mIU/liter) and in subjects with "high-normal" serum TSH levels (TSH: 2.01-4.0 
microIU/mL) compared to a control group (38).  
The negative effects of SubHypo on cardiovascular function could be improved or 
reversed by replacement doses of levothyroxine (LT4). Randomized controlled trials 
showed that LT4 treatment improved endothelial function, systolic and diastolic 
function and carotid intima-media thickness in patients with SubHypo (5, 6, 39-43).  
Taddei et al. analyzed the FMD response to intrabrachial acetylcholine infusion at 
baseline and during infusion of a NO synthase inhibitor (NG-monomethyl-l-arginine - 
L-NMMA) in young, non-obese, non-smokers and non-hypertensive SubHypo patients 
before and after LT4 therapy (39). The authors evaluated the response to sodium 
nitroprusside and minimal forearm vascular resistances too. In SubHypo patients, 
vasodilation to acetylcholine was reduced compared to euthyroid subjects, while the 
response to sodium nitroprusside (which specifically acts  on  vascular smooth  muscle  
cells) was similar in patient with or without SubHypo. Patients with SHypo had  
12 
 
endothelial dysfunction with a reduction in NO availability; this alteration was 
partially independent of dyslipidemia and reversed after six months of LT4 
supplementation (39). 
In a  subsequent randomized crossover trial, FMD improved significantly in patients 
with SubHypo after replacement LT4 therapy, independently of other cardiovascular 
risk factors (40). The enhancement in FMD response could suggest a better NO 
production and an improvement in endothelial function in clinically relevant areas of 
the vasculature, such as coronary and carotid circulation (40).  
In a double-blind placebo controlled study a reduction in carotid artery intima-media 
thickness (an atherosclerosis parameter) after replacement therapy with LT4 in patient 
with SubHypo was also reported. This reduction was directly related to the decrease of 
both total cholesterol and TSH values after therapy (41). 
Numerous factors could potentially contribute to arterial stiffness and endothelial 
dysfunction in SubHypo as in overt hypothyroidism. Hyperlipidemia has an important 
role in atherosclerosis development (41). SubHypo patients may have higher 
Triglycerides, LDL-Cholesterol and apolipoprotein B levels and higher mean intima-
media thickness values, compared with euthyroid patients matched fox sex and age 
(40). Thyroid autoantibodies might also have a potential role in inflammatory 
processes associated to endothelial dysfunction. In patients with SubHypo due to 
thyroid autoimmunity, the endothelial dysfunction after LT4 therapy was only partially 
reversed (41). Low-grade chronic inflammation due to Hashimoto’s thyroiditis (an 
autoimmune thyroid disease) induced an impaired NO availability by COX-2-
dependent pathway in patients with SubHypo (41). Both hyperlipidemia and thyroid 
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antibodies are able to reduce the eNOS expression impairing NO production and 
endothelium-dependent vasomotor function (41).  
Furthermore, thyroid hormone deficiency reduces NO availability in the coronary 
endothelium of mild SubHypo patients without associated cardiovascular risk factors 
(44).  
Thyroid hormone exerts an important effects on the endothelial cell through the 
thyroid hormone receptor α1 and thyroid hormone receptor β. The activation of thyroid 
hormone receptor α1 improved myocardial perfusion, reduced coronary resistance in 
transgenic mouse models (45) and activated of PI3K/AKT signaling and NO synthase 
in endothelial and vascular smooth muscle cells in rat thoracic aortas (46). Thyroid 
hormone binds thyroid hormone receptor β activating  the mitogen-activated protein 
kinase (MAPK) pathway with the activation of proangiogenic genes transcription 
(genes encoding: vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor and angiopoietin) (47, 48).  
Previous studies on circulating markers of endothelial dysfunction have been 
performed (49-51). Tejovathi et al. demonstrated that hypothyroid patients presented 
higher asymmetric dimethyl arginine (ADMA) levels and lower plasma nitrate levels 
compared to euthyroid patients, confirming the presence of endothelial dysfunction in 
hypothyroid patients (49). Xiang et al. investigated the relationship between TNF-
related apoptosis-inducing ligand (TRAIL) and endothelial dysfunction in SubHypo 
patients. They reported that the decreased TRAIL levels in SubHypo patients, were 
positively associated with endothelial function (50). Gungor et al. showed elevated 
endothelial cell-specific molecule-1 (endocan) levels in overt hypothyroid patients, 
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suggesting that endocan levels may be an early biomarker of the development of 
endothelial dysfunction in hypothyroid patients (51). 
In conclusion, based on the data available, overt and subclinical hypothyroidism could 
impair vascular function by altering endothelial function, thus potentially increasing 
the risk of atherosclerosis and coronary artery disease. 
 
1.4 Endothelial dysfunction in overt and subclinical Hyperthyrodism 
 
Hyperthyroidism is characterized by a suppressed serum TSH with elevated thyroid 
hormone levels. Subclinical Hyperthyroidism (SubHyper) represents a condition 
characterized by low or undetectable serum TSH concentration with free T4 and T3 
concentrations within their normal ranges. SubHyper can be divided in two forms: 
endogenous SubHyper, caused by Graves’ disease, autonomously functioning thyroid 
nodules or toxic multinodular goiter, and exogenous SHyper, secondary to an 
intentional  TSH suppression during L-Thyroxine  therapy (5, 6).  
Overt hyperthyroidism is characterized by hyperdynamic cardiovascular function, with 
high cardiac output, improved diastolic function and low systemic vascular resistance 
with a compromised left ventricular  performance during effort  (1-4). 
SubHyper, may induce changes in cardiac morphology (increased left ventricular 
mass) and function (impaired diastolic filling and exercise tolerance) and be 
responsible for alteration in cardiac rhythm (sinus tachycardia, atrial fibrillation, 
increase in atrial and ventricular premature beats) (2, 5, 6, 11). Thyroid hormone 
excess acts on the endothelial component of vascular reactivity, with an NO increase 
production. Napoli et al. observed an increase in NO production with an elevate 
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forearm blood flow in basal state and after acetylcholine infusion in untreated 
hyperthyroid patients with Graves’ disease. These alterations normalized after 
methimazole therapy when euthyroidism was reached (52).  
SubHyper represents a negative prognostic factor for cardiovascular mortality and 
morbidity in the general population (8, 9, 53-55). An increase arterial stiffness and a 
higher carotid intima-media thickness were observed in patients with long term 
SubHyper compared with euthyroid and hypothyroid patients (55). A  meta-analysis of 
large prospective studies of patients with endogenous or exogenous persistent 
SubHyper demonstrated that low serum TSH levels was associated with an increased 
risk of coronary heart disease mortality and all causes of mortality, with highest risks 
in presence of undetectable TSH levels (<0.1 mU/l) (53) 
 
1.5 Endothelial dysfunction and TSH 
 
The thyroid hormones role on the heart and the cardiovascular system has been 
extensively analyzed in patients with subclinical and overt thyroid dysfunctions. On 
the contrary, the potential pathophysiological role of the TSH receptor in the 
cardiovascular system is unclear because it has been poorly investigated in vivo.  In 
fact, only a few studies have assessed the expression of the TSH receptor in the 
cardiovascular system in humans (56-58), mainly because of the difficulty in 
separating its cardiovascular effects from those exerted by thyroid hormones in 
patients with thyroid dysfunction. 
It is unknown, whether the changes in the vasculature associated with thyroid diseases 
may reflect the expression of the direct effect of TSH levels on endothelial cells. 
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The presence of TSH receptor has been reported in vitro in extrathyroid tissues such as 
adipose tissue, smooth muscle cells, red blood cells, hepatocytes and also in 
endothelial cells from umbilical cord and human aortic tissue (59-63). Sellitti et al. 
also observed that TSH receptor mRNA expression was highest in the coronary artery 
of pig heart tissue (60). Donnini et al. reported that TSH increased cAMP and NO 
production in human aortic endothelial cells (62). In the heart, the TSH receptor has 
been found in ventricular myocytes (63). However, the pathophysiological role of TSH 
stimulation through its receptor outside of the thyroid tissue is still unknown.  
The studies conducted so far to evaluate the TSH direct effect in the peripheral 
vascular endothelium in thyroidectomized patients produced conflicting results (56-
58).  Moreover, the effect of TSH on coronary endothelial cells has never been directly 
studied in humans before our study (64). 
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2. Aim of the study 
    
The aim of our study was to investigate the endothelial response of coronary flow 
to recombinant human TSH (rhTSH) in disease-free patients with differentiated 
thyroid cancer (DTC) without cardiovascular risk factors to assess the direct effects of 
TSH on coronary endothelium (64).   
 
This study was of particular interest for several reasons: 
 the direct role of TSH on the coronary endothelial cells has never been 
directly studied;  
 we used a non-invasive method (the evaluation of CFR by trans-thoracic 
eco Doppler) and a physical stressor (CPT); 
 we analyzed thyroidectomized patients with low-risk DTC that represent an 
ideal experimental model to assess the acute TSH effects on the 
cardiovascular function. In fact, low-risk DTC patients require replacement 
doses of L-T4 (65, 66). L-thyroxine (LT4) enables these patients to 
maintain euthyroidism, so that one can evaluate the effects of serum TSH 
without stimulating TSH-dependent thyroid hormone secretion. 
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3. Methods  
 
3.1 Study population  
 
The study population consisted of 10 consecutive patients (3 men and 7 women, mean 
age: 32.6±8 years) who were submitted to total thyroidectomy for DTC in follow up at 
our outpatient thyroid cancer clinic at the "Federico II University Hospital" of Naples. 
The study protocol was approved by the Ethics Committee of the "Federico II 
University Hospital" of Naples and all patients provided informed consent to the 
study. All enrolled patients had a low-risk DTC according to the American Thyroid 
Association Guidelines (absence of local or distant metastases, resection of all 
macroscopic tumor, absence of tumor invasion of locoregional tissues or structures, 
not aggressive histology and, if 
131
I were given, no 
131
I uptake outside the thyroid bed 
on the first post-treatment whole-body scan) (65). No patient had anti-thyroglobulin 
antibodies (AbTg). Low-risk DTC patients were receiving  LT4 doses to maintain TSH 
within normal range (mean dose: 1.97µg/kg/die; range: 1.68-2.16 µg/kg/die). We 
carried out a strict patient selection to exclude all the factors that could confound the 
evaluation of the CFR (47, 64, 67-69). 
Exclusion criteria were pregnancy, obesity (body mass index ≥ 30 kg/m2), arterial 
systemic hypertension, diabetes mellitus, insulin resistance, dyslipidemia, heart 
disease, cardiac rhythm abnormalities, hepatic or renal disorders, cigarette 
smoking, a personal or family history of coronary artery disease and the assumption of 
any kind of medication apart from L-T4. Dyslipidemia was defined as total cholesterol 
≥ 200 mg/dl and/or triglycerides ≥ 160 mg/dl; and arterial hypertension was defined 
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as systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 
90 mmHg. Insulin resistance index, HOMA, was assessed with the homeostasis model 
of insulin resistance (insulinemia [mU/L] × glycemia [mmol/L])/22.5 (27). Coronary 
artery disease was excluded based on clinical history and effort ECG. Hepatic and 
renal diseases were excluded on the basis of the history and laboratory tests 
(transaminases and creatinine) (64).    
 
 3.2 Study protocol   
 
This study was performed during the periodical post-surgical follow-up of our DTC 
patients after the administration of recombinant human TSH (rhTSH) to 
assess stimulated Tg levels. The aim of the DTC post-surgical follow-up is an early 
detection and treatment of persistent or recurrent loco regional or distant disease. 
Therefore follow-up is based on periodic evaluation of basal and stimulated 
thyroglobulin (Tg) after rhTSH administration and neck ultrasound (65). rhTSH is a 
heterodimeric glycoprotein produced by recombinant DNA technology. The rhTSH 
amino acid sequence is identical to the human pituitary TSH and presents the same 
biochemical proprieties. rhTSH has been proposed as an alternative to LT4 withdrawal 
in the staging of patients with DTC (70). 
Patients received two intramuscular injections of rhTSH, at a dose of 0.9 mg each, on 
two consecutive days. Serum TSH, thyroid hormones, Tg and anti-thyglobulin 
antibodies (AbTg), metabolic parameters (weight, height, body mass index (BMI), 
glycemia, total cholesterol and triglycerides) were determined at baseline. Serum TSH, 
thyroid hormones and Tg were re-evaluated 24 hours after the second injection of 
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rhTSH (70). Replacement doses of LT4 were unchanged throughout the study. Patients 
underwent standard Doppler echocardiography with the evaluation of  CFR of the left 
anterior descending artery by the  CPT before and 24 hours after the second rhTSH 
injection (64). 
 
3.3  Assessment of thyroid status  
 
Blood samples for circulating serum TSH, free triiodothyronine (FT3), free thyroxin 
(FT4), Tg and AbTg were collected from the antecubital vein between 7.00 and 8.00 
hours after an overnight fast. TSH levels were measured with the 
electrochemiluminescence immunoassay (ECLIA; Elecsys and Cobas analyzers, 
Roche Diagnostics) that has a sensitivity of at least 0.005 mIU/l, and the reference 
range was 0.3-4.2 mIU/l. Serum FT3 and FT4 were also measured with the ECLIA. 
Sensitivities were <0.400 pmol/l and <0.300 pmol/l for FT3 and FT4, respectively. 
The reference ranges were 3.1-6.8 pmol/l for FT3, and 12-22 pmol/l fo FT4. 
Serum Tg levels were also measured with ECLIA with a sensitivity of 0.1 ng/ml or 
less, and the reference range was 0.1-50 ng/ml.  Serum AbTg levels were measured 
with ECLIA and the reference range was 0-115 IU/ml (64).  
  
3.4 Standard echocardiographic assessment   
 
Echo-Doppler examinations were performed with a Vivid Seven Sound machine 
(GE, Horten, Norway) equipped with a 2.5 MHz phased-array transducer with 
harmonic capability.   
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M-Mode  tracings  were  recorded  in  parasternallong-axis  view,  and  left ventricle,  
left  atrium  and  aortic  root  sizes were  measured  as  previously reported (68). Left 
ventricular mass was calculated according to the American Society of 
Echocardiography recommendations and normalized for height in meters powered to 
2.7 using Simpson method (71). Left ventricular end-diastolic and end-systolic volume 
were measured in apical 4- and 2-chamber views and left ventricular ejection fraction 
calculated according to the standard formula. Standard pulsed Doppler imaging of 
mitral inflow was recorded in the apical four-chamber view. Early (E) and atrial (A) 
peak velocities (m/s) and their ratio, E velocity deceleration time (ms) 
and isovolumetric relaxation time (ms) were measured. Pulsed tissue Doppler-derived 
early diastolic velocity (e’) of septal and mitral annulus were measured and averaged. 
The E/e’ ratio was derived as a non-invasive estimate of left ventricular filling 
pressure. Echo-Doppler methods and the reproducibility of our laboratory are reported 
elsewhere (26, 27). All images were analyzed off-line by two observers who were 
blind to the patients’ clinical characteristics (64).   
  
3.5 Coronary flow reserve   
 
Coronary flow was visualized in the distal left anterior descending artery 
by transthoracic Doppler echocardiography with a 5 MHz shallow-focus phased-array 
transducer. Doppler sample volume was placed on the color signal of the left anterior 
descending artery, and the spectral pulsed Doppler signal was recorded to look for the 
characteristic biphasic flow pattern with a larger diastolic and a smaller systolic 
component both at rest and after the CPT. Coronary diastolic peak flow velocities 
22 
 
(cm/s), heart rate and blood pressure were measured at rest and soon 
after the CPT at maximal endothelial induced hyperemia. The coronary flow 
reserve was calculated as the ratio of hyperemic-to-resting diastolic peak velocities. 
The CPT was performed according to our standardized protocol, by placing the 
subject’s hand and distal part of the forearm in an ice water slurry for 4 minutes (19, 
67). The highest three spectral Doppler signals were averaged for each parameter. The 
reproducibility of our CPT-derived coronary flow reserve measurements of our echo 
laboratory are: an intra-observer variability of 2.0% and an inter-observer variability of 
4.5%, as previously reported (26). All images were analyzed off-line by two observers 
who were blinded to the clinical characteristics of the patients. All examinations were 
performed between 8.00 and 9.00 hours. All patients were fasting and abstained from 
coffee for at least 12 h before testing (64).   
  
3.6 Statistical analysis  
 
SPSS for Window (version 20) was used for statistical analyses. All data are presented 
as mean values ± SD, approximated at the second decimals. The ANOVA test was 
used to assess intergroup differences. Linear regression analyses and the partial 
correlation test using Pearson’s correlation method were used to test univariate 
relations. Differences were considered statistically significant at p<0.05 (64).   
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4. Results  
 
The clinical, demographic and anthropometric characteristics of the patients at 
baseline (before the first injection of rhTSH) are shown in Table 2 (64).  
Eighty consecutive patients were analyzed in our ambulatory. Of these, 46 presented 
one or more exclusion criteria (hypertension, diabetes mellitus, obesity, dyslipidemia, 
heart disease, cardiac rhythm abnormalities, hepatic or renal disorders, cigarette 
smoking, personal or family history of coronary artery disease). 34 patients were 
assessed for eligibility. Five were excluded, during the enrolment, following the 
development of systemic disorders with consequent assumption of medications. 7 
patients were excluded because of elevated BMI (BMI>27 kg/m²) and insulin 
resistance. 2 women became pregnant. 10 patients were eliminated from the study after 
the first cardiological evaluation; of these, 6 patients were excluded for a poor acoustic 
windows and 4 because they refused the second echocardiographic evaluation.  
10 patients which presented all the inclusion criteria were enrolled in this study. Fig. 3 
All of the patients included in  the  study  presented a TMN staging of T1N0M0 and 
had a low risk  of tumor recurrence during the follow-up, according to the American 
Thyroid Guidelines (65).   
In accordance with the exclusion criteria no patient enrolled presented obesity (BMI 
24.51 ± 2.46 kg/m² [data are expressed as means ± SD]), hypertension (SBP 115±14.1 
and DPB 68.5±9.4 mmHg), dyslipidemia (total cholesterol 177.9±16.5 mg/dl and 
triglycerides 66.2±16.8 mg/dl) or hyperglycemia (84.8±6.7 mg/dl). As a consequence 
of replacement doses of L-T4, the TSH level at baseline was 1.25 ± 0.37 µU/ml and 
serum FT3 and FT4 were within the normal range. No patient had AbTg or 
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elevated Tg values. The left ventricular structure, and systolic and diastolic function at 
echo-Doppler analysis were normal in all patients  (64) Table 3.   
Table 4 shows the results of the CFR at baseline and at 24 h after second rhTSH 
injection (64). Mild side effects, such as nausea and headaches, never occurred during 
rhTSH administration. TSH levels were significantly higher than baseline after rhTSH 
administration (147±37 vs 0.7±0.3; p <0.001), whereas thyroid hormones, FT3 and 
FT4, Tg and AbTg levels remained unchanged (64). Similarly,  rhTSH administration 
did not affect SBP (115±14.1 at baseline vs 119±13.1  after rhTSH), DBP (68.5± 9.4 
vs 73±9.7), mean blood pressure (85±9.9 vs 83±6,4) or heart rate (75.9±12.9 vs 
74.6±12.2). Coronary flow peak velocity at rest was similar at baseline and 24 hours 
post-rhTSH (22.3 ± 6 vs 23.2 ± 8.7; p = 0.66), whereas coronary flow peak velocity 
after CPT was higher after rhTSH administration (29.3 ± 6.8 vs 34.4 ± 10.9; p<0.05).  
Of consequence, CFR was significantly higher after administration of rhTSH (1.3 ± 
0:2 vs. 1.5 ± 0.2, p <0.01). The increase in myocardial work, reflected by the increase 
in the rate pressure product (SBP x heart rate), was significantly higher after rhTSH 
administration (8887.1 ± 2883.4 vs 9880.7 ± 2717.9, p<0.05), and was associated with 
a proportionate increase in myocardial blood flow (64).   
Figure 4 shows the CPT-derived coronary flow at baseline and 24 hours after the 
second rhTSH injection in one patient (64).  Figure 5 shows changes in coronary flow 
velocities after the cold pressure test at baseline and 24 h after the second rhTSH 
administration in each patient (64). We found that coronary flow improved after 
rhTSH administration in 8/10 patients (80%). The CFR 24 hours after the second 
rhTSH injection was not significantly related to heart rate (p=0.4), SBP (p=0.6),DPB 
(p=0.5), left ventricular mass (p=0.8), relative wall thickness (p=0.5), indices of left 
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ventricular diastolic function (a peak velocity p=0.7; e peak velocity p=0.7; e/a ratio 
p=0.7), systolic function (p=0.1), fasting blood glucose (p=0.6), total cholesterol 
(p=0.8), triglycerides (p= .0.6), BMI (p=0.2) or TSH (p=0.7) (64).  
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5. Discussion  
 
The present study evaluates the effect of TSH on the coronary endothelial function 
in athyreotic patients without cardiovascular risk factors during treatment with 
replacement doses of  LT4 (64). All the patients enrolled were young, non-obese, non-
smokers with normal blood pressure, normal cholesterol levels and absence of  a personal 
or family history of coronary artery disease. The administration of rhTSH did not change 
heart rate, cardiac rhythm, left ventricular structure or systolic and diastolic function in 
our thyroidectomized patients, as previous reported (72). Moreover, the non-
pharmacological stressor CPT improved the CFR after rhTSH administration in DTC 
patients (64).  
The evaluation of rhTSH effects on the endothelium have been reported conflicting 
results (56-58). Napoli et al. analyzed the positive effects of TSH in vascular homeostasis 
in large conduit arteries and small resistance vessels using forearm blood flow dilatation 
measured by plethysmography (56,57). Acute intrabrachial administration of rhTSH 
enhanced endothelium-dependent vasodilatation (evaluated during acetylcholine 
infusion) but not endothelium-independent vasodilatation (evaluated during 
nitroglycerine administration) in thyroidectomized patients and health volunteers. Acute 
rhTSH administration improved endothelial function in the small resistance vessels, 
irrespective of thyroid hormone secretion (56). Similarly, in another study, the authors 
evaluated the role of TSH on large arteries in thyroidectomized patients with DTC using 
FMD of the brachial artery. They reported a marked and persistent activation of the 
endothelial-mediated vasodilatation persisted for 5 days after the rhTSH administration, 
independent of systemic hemodynamic changes (57). The results of this study supported 
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that the acute administration of rhTSH is able to enhance vascular reactivity in the human 
conduit arteries. This response was mediated by endothelial mechanisms as witnessed by 
the finding that rhTSH did not alter the response to nitroglycerin, which 
is a vasorelaxing agent that acts directly on smooth muscle cells (57, 64). 
On the contrary, in another study the administration of rhTSH acutely impaired 
endothelium-dependent vasodilatation possibly by inducing low-grade inflammation in 
patient with DTC; a sharp rise in serum TSH induced a significant reduction in FMD 
with an increase in blood inflammatory markers (IL6, TNFα) (56). The discrepancy 
between these studies may be related to the different methods used to evaluate 
endothelial function. In fact, FMD analyzes the conduit arteries (58), whereas 
plethysmography explores resistance vessels (56). Furthermore, one study evaluated 
athyreotic patients receiving replacement doses of LT4 (56), whereas the other assessed 
the acute effects of rhTSH in patients receiving TSH suppressive LT4 therapy  (58).   
In the present study, we demonstrated that CPT improves the CFR after rhTSH 
administration in DTC patients receiving replacement doses of LT4 (64) (Table 4). The 
improvement of CFR was mainly determinate to a significant increase of CPT-derived 
coronary flow. The increase of post-CPT coronary blood flow after rhTSH administration 
could be related to the direct vascular effect of rhTSH on the coronary endothelial cells 
and not mediated by thyroid hormones action. The improvement of post-CPT coronary 
blood flow after rhTSH administration was not associated with a similar increase at rest.  
The positive coronary effect could not be considered a reflex response or a consequence 
of rhTSH action exerted elsewhere in the cardiovascular system because we did not find 
any cardiac morphology or function alterations, or changes in arterial blood pressure and 
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heart rate. The absence of AbTg in our study population excludes the possibility of an 
additional role of inflammation and autoimmunity on the endothelial function (64).   
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6. Study limitations  
 
The study presents few limitations. One limitation is the small study population size, 
which may have resulted in the lack of statistical significance of some 
parameters. However, despite a large standard deviation of rhTSH-derived coronary 
flow velocity both at rest and after CPT (which demonstrates a degree of overlapping 
between baseline and rhTSH results), the difference of the same CPT-derived coronary 
flow was statistically significant, it being increased after rhTSH in 80% of the patients 
assessed. This result highlights therefore the effect of rhTSH on coronary endothelial 
function. Nevertheless, it was difficult to enroll young patients with low-risk DTC 
without cardiovascular risk factors or a family history of coronary disease that were 
willing to undergo coronary reserve flow evaluation during rhTSH administration 
(64). The second study limitation is the absence of a well-established cut-off value 
for CFR evaluated after CPT stimulation. We know that the CPT is less powerful than 
pharmacological stimulation in NO release by endothelial cells. For these reason the 
cut-off values can be considered lower (<2), which is the validated cut-off for CFR 
after pharmacological stimulation (adenosine or dipyridamole). We choose CPT rather 
than pharmacological stressors because  adenosine or dipyridamole determinate a 
coronary flow increase of which is only partially endothelium-dependent.  However 
CPT stimulation has been validated in previous studies (38, 44) and our results in 
SubHypo patients supported this lower cut-off (44).    
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7. Conclusions  
 
Our data demonstrate that acute administration of rhTSH is associated with a significant 
improvement in the coronary flow reserve. This occurs in response to physiological 
stimulus induced by CPT as results of increased vascular reactivity mediated by a 
mechanism of endothelium-mediated vasodilatation. Our results suggest that TSH itself 
exerts a protective role on the coronary endothelium. This effect could suggest a 
protective TSH action on coronary endothelium that is direct and not mediated by thyroid 
hormones  modification, because no change in serum FT3 and FT4 levels were observed 
after rhTSH administration (64).  The TSH protective role on the coronary endothelium 
could explain the negative effects of TSH suppression on cardiovascular disease in 
patients with SubHyper. Patients with DTC had a higher risk of cardiovascular mortality 
and  low or undetectable TSH levels predicted cardiovascular mortality (73). Therefore, 
the cardiovascular risk was significantly higher in patients with lower TSH values (53). 
The mechanism that determinate this amplified vascular risk is unclear and it is in 
contrast with the positive effects that thyroid hormone excess has on endothelial function 
and metabolic parameters (52).  
The positive TSH effect on the coronary endothelium reported in our study could suggest  
that SubHyper has negative effects on coronary heart disease determinate by a persistent 
suppression in TSH, despite the slight increase in thyroid hormone at tissue level levels  
(64).  
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8. Tabels 
 
Table 1. Advantages and Disadvantages of the Techniques to Assess Endothelial Function 
Methods   Vascular Bed Advantages Disadvantages Stimulus  
 
CFR Coronary 
microvascular  
Non invasive  
Easy access 
 
Challenging for 
serial measurements 
Dipyridamole 
Adenosine 
CPT 
Coronary 
microvascular 
function by 
Coronary 
angiography  
 
Epicardial 
macrovascular 
 
Conduit arteries 
Assessment directly 
in the coronary 
vascular bed 
 
 
Invasive  
Expensive  
Risks connected to 
coronary 
angiography 
Challenging for 
serial measurements 
Ach 
Exercise 
Pacing  
CPT 
 
Coronary 
microvascular 
function–Doppler 
wires 
Coronary 
microvascular  
 
Resistance arteries 
Assessment directly 
in the coronary 
microvasculature 
 
Invasive 
Expensive  
Time intensive  
Risks connected to 
coronary 
angiography 
Challenging for 
serial measurements 
Ach 
Adenosine 
Papaverine 
Flow mediated 
dilatation 
(FMD) 
Brachial artery  
 
Conduit artery 
Easy access 
Correlation with 
invasive epicardial 
vascular function 
Inexpensive 
Possibility to assess 
other important 
parameters (flow, 
baseline arterial 
diameters, FMC) 
Directly correlated 
with coronary 
endothelial 
dysfunction  
Challenging to 
perform well  
Disparate protocols 
for performance 
and standardizations 
Variable measures 
Reactive 
Hyperemia 
Plethysmography Forearm vasculature  
 
Microvasculature 
Easy access  
Vasoactive 
substances infused  
to generate a dose-
response 
relationship 
Contralateral arm as 
a control 
Invasive 
(cannulation of the 
brachial 
artery) but less 
invasive than 
coronarography 
Time consuming 
 
Ach and other 
vasoactive 
Substances 
EndoPAT Finger  
Microvasculature 
Easy to access and 
perform  
automated 
Low interobserver 
variability 
Correlation with 
invasive 
microvascular 
vascular function 
Expense of 
disposable finger 
probes 
PAT signal 
influenced by 
variable 
and non-endothelial 
factors 
Reactive 
hyperemia 
Ach, acetylcholine; CPT, cold pressor test; FMC, flow-mediated constriction; PAT, peripheral arterial tonometry 
Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Lüscher 
TF, Shechter M, Taddei S, Vita JA, Lerman A. The assessment of endothelial function: from research 
into clinical practice. Circulation. 2012; 126(6):753-67. Review (16) 
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Table 2  Characteristics of the study population* 
Clinical data  
Age (years) 32.6 ± 8 
Body weight (kg)  69.5 ± 11.4 
Height (m) 1.6 ± 0.1 
Body mass index (kg/m
2
) 24.5 ± 2.4 
 
Hemodynamic characteristics  
Systolic blood pressure (mmHg) 115 ±14.1 
Diastolic blood pressure (mmHg) 68.5 ± 9.4 
Heart rate (beats/min) 75.9 ± 12.9 
 
Metabolic profile   
Glycemia (mg/dl) 84.8 ± 6.7 
Total cholesterol (mg/dl) 177.9 ± 16.5 
Triglycerides (mg/dl) 66.2 ± 16.8  
 
Thyroid profile  
TSH (µU/ml) 0.7 ± 0.3 
FT3 (pmol/l) 5.2 ± 0.7 
FT4 (pmol/l) 19.2± 2.7 
Ab Tg (lU/ml) 18.4 ± 14.8 
Tg (ng/dl) 0.14 ± 0.21 
 
*Data are expressed as means ± SD 
 
Ippolito S, Ippolito R, Peirce C, Esposito R, Arpaia D, Santoro C, Pontieri G, Cocozza S, Galderisi M, 
Biondi B. Recombinant human thyrotropin improves endothelial coronary flow reserve in 
thyroidectomized  patients with differentiated thyroid cancer. Thyroid. 2016;26(11):1528-1534 
(64) 
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Table 3 Doppler echocardiography analysis 
  
  E: transmitral early peak diastolic velocity 
 A: transmitral atrial peak velocity 
 e’: early diastolic velocity of septal annulus 
 
Ippolito S, Ippolito R, Peirce C, Esposito R, Arpaia D, Santoro C, Pontieri G, Cocozza S, Galderisi M, 
Biondi B. Recombinant human thyrotropin improves endothelial coronary flow reserve in 
thyroidectomized  patients with differentiated thyroid cancer. Thyroid. 2016; 26(11):1528-1534  
(64) 
  
Variables Values Reference range  
Left ventricular mass index (g/m²) 67.7 ± 13.7 <95 (W), <115(M) 
Relative wall thickness 0.3 ± 0.04 <0.42 
Left ventricular ejection fraction (%) 63.7± 6.6 ≥53 
Left atrial volume index (ml/m
2.7
) 29.9 ± 5.46 <34  
Transmitral peak velocity E/A ratio 1.2 ± 0.2 0.73-2.33 
E velocity deceleration time (ms) 167.8± 24.5 160-240 
E/e' ratio  7.8 ± 1.6 <13 
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Table 4 Coronary flow reserve 
Variables Baseline CFR  CFR after 
rhTSH 
p 
TSH (µU/ml)  1.25 ± 0.3 147 ± 37 <0.001 
FT3 (pmol/l) 5.2 ± 0.7 5.2 ± 0.2 NS (p=0.17) 
FT4 (pmol/l) 19.2± 2.7 19.2 ±2.5 NS (p=0.2) 
Ab Tg (lU/ml) 18.4 ± 14.8 18.2 ±14.3 NS (p=0.55) 
Tg (ng/dl) 0.14 ± 0.21 0.4 ± 0.35 NS (p=0.08) 
Coronary flow velocity at rest 
(cm/s)  
22.3 ± 6 23.2 ± 8.7 NS (p=0.66) 
SBP at rest (mmHg) 115 ± 14.1 119 ± 13.1 NS (p=0.3) 
DBP at rest (mmHg) 68.5 ± 9.4  73 ± 9.7 NS (p=0.27) 
Mean BP at rest (mmHg) 81.6 ± 10.3 82.3 ± 6.5 NS (p=0.85) 
Heart rate at rest  75.9 ± 12.9 74.6 ± 12.2 NS (p=0.64) 
Coronary flow velocity after CPT 
(cm/s)  
29.3 ± 6.8 34.4 ± 10.9 p <0.05 
SBP after CPT (mmHg) 111.4 ± 12.1 115.7 ± 12.3 NS (p=0.17) 
DBP after CPT (mmHg)  67.8 ± 5.6 72.1 ± 3.9 NS (p=0.11) 
Mean BP after CPT (mmHg) 85.5 ± 7.3 88.3 ± 6.7 NS (p=0.90) 
Heart rate after CPT  76.5 ± 16.8 82.7 ± 17.4 NS (p=0.14) 
Coronary flow reserve  1.32 ± 0.21 1.53 ± 0.2 p<0.01 
 
Data are expressed as means ± SD 
CPT: cold pressure test; SBP: systolic blood pressure; DBP: diastolic blood pressure. 
 
 
Ippolito S, Ippolito R, Peirce C, Esposito R, Arpaia D, Santoro C, Pontieri G, Cocozza S, Galderisi M, 
Biondi B. Recombinant human thyrotropin improves endothelial coronary flow reserve in 
thyroidectomized  patients with differentiated thyroid cancer. Thyroid. 2016;26(11):1528-1534 
(64) 
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9. Figures  
 
 
Figure 1 Genomic and nongenomic effect of thyroid hormones on the cardiomyocytes  
T3 binds to thyroid hormone receptors (TRs) in the nucleus.  
Thyroid hormones positively regulate the transcription of myosin heavy chain-α and 
sarcoplasmic/endoplasmic reticulum calcium ATPase 2. On the contrary, genes that are negatively 
regulated by thyroid hormones are those that encode myosin heavy chain-β and phospholamban 
(PLN).  
Nongenomic actions of thyroid hormones include regulation of voltage-gated K+ channels, Na+/K+ 
ATPase, and the Na+/Ca2+ exchanger, and activation of survival pathways.  
 
T3: Triiodotironine; T4: Thyroxine; AKT:serine/threonine-protein kinase; MAPK: mitogen-activated 
protein kinase; PI3K: phosphatidylinositol 3-kinase; SERCA: sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 ; PLN : Phosfolamban 
 
 
Modified by Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and 
cardiovascular disease. Nat Rev Cardiol. 2017; 14(1):39-55. Review.   
(3) 
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Fig. 2 Multiple endothelial functions  
 
Nitric oxide released from endothelial cells is responsible for a number of physiological functions: 
1) regulation of vascular tone through balanced production of vasodilators and vasoconstrictors, 
2) control of blood fluidity and coagulation through production of factors that regulate platelet 
activity, the clotting cascade, and the fibrinolytic system  
3) regulation of inflammatory processes through expression of cytokines and adhesion molecules.  
  
Endothelium  
 
Vascular  tone 
 
Angiogenesis  
 
Inflammatory 
pattern  
 
Cell Proliferaton 
 
Platelet 
 adhesion and 
aggregation 
 
Fibrinolysis 
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Fig. 3 Flowchart of the patients’ selection  
 
  
 
Selected patients  
 
(n=34) 
  Patients excluded after first evaluation  
(n= 14) 
• medications (5) 
• insulin resistence (7) 
• pregnant women (2) 
 Patients excluded after cardiological 
evaluation 
(n=10)  
• poor acustic windows (6) 
• refused 2° evaluation (4) 
Enrolled patients  
(n=10) 
Patients excluded for the presence of one  
or more exclusion criteria 
(n=46) 
• hypertension (8) 
• diabete mellitus (5) 
• obesity (6) 
• cardiac rhythm  
alterations (2) 
 
 Elegible patients with  
Low risk DTC 
(n= 80) 
 
• smoke (13) 
• dyslipidemia (7) 
• renal disorders (2) 
• family history of coronary 
heart disease (3) 
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Fig.4 Cold pressure test (CPT)-induced coronary flow reserve at baseline and 24 h after 
the second recombinant human thyrotropin (rhTSH) injection in a single patient. 
Upper panel: Coronary flow velocities at rest and after CPT at baseline. 
Lower panel: Coronary flow velocity at rest and after CPT 24 h after the second rhTSH injection. 
 
Ippolito S, Ippolito R, Peirce C, Esposito R, Arpaia D, Santoro C, Pontieri G, Cocozza S, Galderisi M, 
Biondi B. Recombinant human thyrotropin improves endothelial coronary flow reserve in 
thyroidectomized  patients with differentiated thyroid cancer. Thyroid. 2016; 26(11):1528-1534  
(64) 
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Fig.5 Changes in coronary flow after CPT at baseline and 24 h after second rhTSH 
administration. 
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(64) 
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